Compare SUPV & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUPV | ACRS |
|---|---|---|
| Founded | 1887 | 2012 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.4M | 868.5M |
| IPO Year | 2015 | 2015 |
| Metric | SUPV | ACRS |
|---|---|---|
| Price | $8.69 | $6.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $13.00 | $10.20 |
| AVG Volume (30 Days) | 662.2K | ★ 1.6M |
| Earning Date | 05-26-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $86.20 | N/A |
| Revenue Next Year | $25.12 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.54 | $1.74 |
| 52 Week High | $13.55 | $6.60 |
| Indicator | SUPV | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 50.77 | 48.86 |
| Support Level | $7.70 | $5.64 |
| Resistance Level | $8.92 | $6.56 |
| Average True Range (ATR) | 0.44 | 0.31 |
| MACD | 0.12 | -0.06 |
| Stochastic Oscillator | 77.27 | 26.23 |
Grupo Supervielle SA a diversified financial services group in Argentina. It offers a broad range of financial products and services including lending, savings and investments, insurance, payments and cash management services, car loans, and asset management, positioning itself as a one-stop destination for financial needs. It operates exclusively in Argentina, through the Bank, which serves as its main banking subsidiary, delivering a comprehensive suite of financial services to retail, SMEs and corporate customers. Its segments include Personal & Business Banking; Corporate Banking; Bank Treasury; Insurance; and Asset Management and Other Services (which includes IOL invertironline). The majority of the revenue is derived from Personal & Business Banking segment.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.